Almost 7 million people are living with Alzheimer’s disease (AD) in the United States alone.1 This number is expected to increase by 100% by 2060,1 putting even more pressure on researchers to quickly deliver meaningful breakthroughs on effective therapies. But, from highly specific inclusion criteria to advanced imaging and biomarker assessments, Alzheimer’s clinical trials are [...]